Leerink Swann Reconfirms Mirati Therapeutics (NDAQ:MRTX) As a Mkt Perform; They Now Have a Target Of $9.00

September 17, 2017 - By Dolores Ford

 Leerink Swann Reconfirms Mirati Therapeutics (NDAQ:MRTX) As a Mkt Perform; They Now Have a Target Of $9.00

Investors sentiment decreased to 0.81 in 2016 Q4. Its down 0.23, from 1.04 in 2016Q3. It worsened, as 12 investors sold Mirati Therapeutics, Inc. shares while 19 reduced holdings. 7 funds opened positions while 18 raised stakes. 9.10 million shares or 3.41% less from 9.42 million shares in 2016Q3 were reported.

Blackrock Limited Liability Corp stated it has 0% in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Susquehanna Interest Group Limited Liability Partnership holds 23,127 shares. Barclays Public Ltd Company reported 522 shares. National Bank & Trust Of Ny Mellon has invested 0% of its portfolio in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Bnp Paribas Arbitrage holds 758 shares. 43,605 were accumulated by Blackrock Inv Management Limited Liability Company. Geode Cap Mgmt Llc holds 109,262 shares. Ghost Tree Capital Limited Liability holds 0.2% or 172,184 shares. Rhumbline Advisers holds 0% or 11,629 shares. Franklin Res has invested 0% of its portfolio in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Great Point Ptnrs Ltd Llc reported 870,261 shares. Blackrock Institutional Tru Company Na invested in 0% or 352,282 shares. Trexquant Investment Limited Partnership holds 26,432 shares or 0.02% of its portfolio. Nationwide Fund Advsrs accumulated 7,245 shares. Legal And General Gru Public Ltd holds 0% or 3,790 shares.

Mirati Therapeutics (NDAQ:MRTX) Rating Reaffirmed

They currently have a $9.00 TP on Mirati Therapeutics (NDAQ:MRTX). The target price by Leerink Swann would suggest a potential downside of -19.64 % from the company’s last stock price. This has been released in an analyst note on Friday, 15 September.

Investors sentiment decreased to 0.81 in 2016 Q4. Its down 0.23, from 1.04 in 2016Q3. It worsened, as 12 investors sold Mirati Therapeutics, Inc. shares while 19 reduced holdings. 7 funds opened positions while 18 raised stakes. 9.10 million shares or 3.41% less from 9.42 million shares in 2016Q3 were reported.

Blackrock Limited Liability Corp stated it has 0% in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Susquehanna Interest Group Limited Liability Partnership holds 23,127 shares. Barclays Public Ltd Company reported 522 shares. National Bank & Trust Of Ny Mellon has invested 0% of its portfolio in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Bnp Paribas Arbitrage holds 758 shares. 43,605 were accumulated by Blackrock Inv Management Limited Liability Company. Geode Cap Mgmt Llc holds 109,262 shares. Ghost Tree Capital Limited Liability holds 0.2% or 172,184 shares. Rhumbline Advisers holds 0% or 11,629 shares. Franklin Res has invested 0% of its portfolio in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Great Point Ptnrs Ltd Llc reported 870,261 shares. Blackrock Institutional Tru Company Na invested in 0% or 352,282 shares. Trexquant Investment Limited Partnership holds 26,432 shares or 0.02% of its portfolio. Nationwide Fund Advsrs accumulated 7,245 shares. Legal And General Gru Public Ltd holds 0% or 3,790 shares.

The stock increased 135.79% or $6.45 on September 15, reaching $11.2. About 48.77 million shares traded or 2686.86% up from the average. Mirati Therapeutics, Inc. (NDAQ:MRTX) has declined 76.51% since September 17, 2016 and is downtrending. It has underperformed by 93.21% the S&P500.

Investors wait Mirati Therapeutics, Inc. (NASDAQ:MRTX) to report on November, 2. its quarterly earnings Wall Street analysts expect $-0.85 earnings per share, up $0.12 or 12.37 % from last year’s $-0.97 same quarter earnings. Mirati Therapeutics, Inc.’s Wall Street analysts see 14.86 % negative EPS growth, taking into account the $-0.74 EPS reproted in the previous quarter,

More notable recent Mirati Therapeutics, Inc. (NASDAQ:MRTX) news were published by: Seekingalpha.com which released: “Mirati Therapeutics: Is This $5 Busted IPO A Buy, Sell, Or Hold?” on July 31, 2017, also Benzinga.com with their article: “Mid-Day Market Update: Mirati Therapeutics Climbs Following Positive …” published on September 15, 2017, Prnewswire.com published: “Mirati Therapeutics Announces Proposed Public Offering of Common Stock” on January 05, 2017. More interesting news about Mirati Therapeutics, Inc. (NASDAQ:MRTX) were released by: Prnewswire.com and their article: “Mirati Therapeutics To Participate In Immuno-Oncology Panel Discussion At The …” published on August 30, 2017 as well as Prnewswire.com‘s news article titled: “Mirati Therapeutics Announces Closing of Public Offering of Common Stock and …” with publication date: January 11, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.